Autres langues Cellectar Biosciences, Inc.

Actions

CLRB

US15117F8804

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 12/10/2026			Varia. 5j.	Varia. 1 janv.
1,430 ^USD	-1,38%		-14,37%	-51,53%

29/09	Cellectar Biosciences annonce une analyse de sous-groupe des données de l’essai clinique de phase 2 CLOVER WaM sur l’iopofosine I 131 chez des patients atteints de macroglobulinémie de Waldenström réfractaires ou résistants à un traitement par inhibiteur de la tyrosine kinase de Bruton (BTK)	CI
18/08	Transcript : Cellectar Biosciences, Inc. - Special Call

Autres langues

29/09	Cellectar Biosciences Announces Subset Analysis of Data from Phase 2 Clover Wam Clinical Trial of iopofosine I 131 in Patients Refractory or Resistant to BTK Inhibitor Therapy
29/09	Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
13/08	Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
13/08	Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
27/07	Translogistics Inc. Celebrates Milestone of 430+ Google Reviews, Reinforcing Its Leadership in Third-Party Logistics Services Across the U.S.
15/07	Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
01/06	Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
01/06	Cellectar Biosciences Highlights New Efficacy Data from Phase 2B Clover Wam Study of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia
19/05	Cellectar Biosciences Files for Secondary Offering of Common Shares
18/05	Cellectar Biosciences, Inc. Announces Board Changes
14/05	Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
14/05	Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
06/05	Cellectar Biosciences, Inc. announced that it has received $30.708034 million in funding from Balyasny Asset Management L.P., Nantahala Capital Management, LLC, Caligan Partners, LP, Janus Henderson Investors US LLC, Silverarc Capital Management, LLC and other investors
05/05	Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
05/05	Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2B Clover Wam Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia
05/05	Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
05/05	Cellectar Biosciences, Inc. Appoints Andrew Gu to Board of Directors
22/04	Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Chief Financial Officer, Effective as of May 1, 2026
22/04	Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Principal Accounting Officer, Effective as of May 1, 2026
21/04	Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
21/04	Cellectar Biosciences Announces Subset Of Clover Clinical Trial Data Accepted For Presentation At American Society Of Clinical Oncology Conference
14/04	Cellectar Biosciences Enrolls First Patient in Clr 125 Auger-Emitting Radioconjugate Phase 1B Clinical Trial Targeting Refractory Triple Negative Breast Cancer
14/04	Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)